Physician profile
Amber L Daugherty
NPI 1124273875
$1,731.19
in general payments reported to CMS, 2019-2025
23 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $62.02 · 2021: $57.76 · 2022: $175 · 2023: $413 · 2024: $401 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $223.11 | 2022-2025 | Vraylar |
| Amgen INC. | $165.73 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $146.67 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $125.05 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $123.56 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.70 | 2019-2023 | Jardiance |
| Pfizer INC. | $81.67 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $70.25 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $64.17 | 2019-2024 | Dificid |
| Lilly USA, LLC | $60.27 | 2023-2024 | Mounjaro |
| Mylan Specialty L.P. | $49.54 | 2021-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $44.81 | 2019-2024 | Spravato |
| Exact Sciences Corporation | $36.15 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $32.55 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.01 | 2023-2024 | Trulance, Xifaxan |
| Dexcom, INC. | $24.47 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $24.06 | 2019-2020 | |
| Corcept Therapeutics | $23.45 | 2025 | Korlym |
| Lundbeck LLC | $21.27 | 2024 | Vyepti |
| Tactile Systems Technology INC | $17.63 | 2019 | |
| Dynavax Technologies Corporation | $16.56 | 2023 | Heplisav-B |
| Allergan, INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.